Search research articles
Contact Us
Filters
Showing results (1-10 of 168) with videos related to
Page
of 17
Sort By:
The Oncologist
|
April 19, 2002
Molecular targets of arsenic trioxide in malignant cells
Wilson H Miller
Journal of Molecular Endocrinology
|
September 16, 2022
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy
Victoria Korsos, Wilson H Miller
Cancer Cell
|
April 20, 2004
Death by arsenic: implications of PML sumoylation
Koren K Mann, Wilson H Miller
Molecular Cancer Therapeutics
|
June 21, 2008
Arsenic trioxide decreases AKT protein in a caspase-dependent manner
Koren K Mann, Myrian Colombo, Wilson H Miller
Seminars in Hematology
|
May 16, 2002
Arsenic trioxide: mechanisms of action
Kelly Davison, Koren K Mann, Wilson H Miller
Best Practice & Research. Clinical Haematology
|
June 8, 2014
Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide
Jessica N Nichol, Nicolas Garnier, Wilson H Miller
Molecular and Cellular Biology
|
January 24, 2008
Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance
Suzan McNamara, Hongling Wang, Nessrine Hanna, et al.
Expert Opinion on Therapeutic Targets
|
July 10, 2014
Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond
Filippa Pettersson, Sonia V Del Rincon, Wilson H Miller
Frontiers in Bioscience (Landmark Edition)
|
March 11, 2009
Expanding PML's functional repertoire through post-translational mechanisms
Jessica N Nichol, Luca A Petruccelli, Wilson H Miller
Blood
|
July 17, 2004
Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells
Michael Witcher, Hoi Ying Shiu, Qi Guo, et al.
Page
of 17
Search research articles
Search
Showing results (1-10 of 168) with videos related to
Sort By:
Page
of 17
The Oncologist
|
April 19, 2002
Molecular targets of arsenic trioxide in malignant cells
Wilson H Miller
Journal of Molecular Endocrinology
|
September 16, 2022
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy
Victoria Korsos, Wilson H Miller
Cancer Cell
|
April 20, 2004
Death by arsenic: implications of PML sumoylation
Koren K Mann, Wilson H Miller
Molecular Cancer Therapeutics
|
June 21, 2008
Arsenic trioxide decreases AKT protein in a caspase-dependent manner
Koren K Mann, Myrian Colombo, Wilson H Miller
Seminars in Hematology
|
May 16, 2002
Arsenic trioxide: mechanisms of action
Kelly Davison, Koren K Mann, Wilson H Miller
Best Practice & Research. Clinical Haematology
|
June 8, 2014
Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide
Jessica N Nichol, Nicolas Garnier, Wilson H Miller
Molecular and Cellular Biology
|
January 24, 2008
Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance
Suzan McNamara, Hongling Wang, Nessrine Hanna, et al.
Expert Opinion on Therapeutic Targets
|
July 10, 2014
Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond
Filippa Pettersson, Sonia V Del Rincon, Wilson H Miller
Frontiers in Bioscience (Landmark Edition)
|
March 11, 2009
Expanding PML's functional repertoire through post-translational mechanisms
Jessica N Nichol, Luca A Petruccelli, Wilson H Miller
Blood
|
July 17, 2004
Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells
Michael Witcher, Hoi Ying Shiu, Qi Guo, et al.
Page
of 17